Background: Relatively few studies have explored the impact of home telerehabilitation-based (HTB) programs on patients with post-COVID-19 syndrome. Thus, this study aimed to investigate the effect of HTB programs on the cardiopulmonary function, body composition, muscle strength, and quality of life (QoL) of patients with post-COVID-19 syndrome.
Methods: A quasi-experimental study was performed. Fifty-one patients with COVID-19 were divided into two groups after being discharged from the hospital. Participants in the control group (n = 26) were advised to engage in breathing and stretching exercises plus their preferred exercise program. In comparison, participants in the intervention group (n = 25) were instructed to perform a combination of aerobic, breathing, and resistance exercises. To monitor the exercise program at home, the physiotherapists called the participants using a mobile phone application platform once a month and once a week in the control and intervention groups, respectively. Outcome measurements consisted of cardiopulmonary functions including exercise capacity using the 6-min walk test (6 MWT), and the pulmonary function test (PFT). Leg muscle strength and endurance were determined using the 1-min sit-to-stand test (1MSTS). Other physical fitness parameters were also examined including the hand grip strength test and body composition attributes. The 36-item Short Form questionnaire was used to determine the quality of life. All outcome measurements were tested before hospital discharge and at 3-month follow-up.
Results: Participants of the control ( = 18) and intervention ( = 14) groups completed a 3-month post-discharge exercise program. No statistically significant differences were found between the two groups for all outcome measurements ( > 0.05). However, the 6 MWT and 1MSTS values increased significantly at the time of the 3-month follow-up compared to the baseline values at the time of discharge for both groups.
Conclusion: Patients with post-COVID-19 syndrome exhibited beneficial effects on exercise capacity, leg muscle strength, and endurance after completing a 3-month duration post-discharge HTB program.
Trial Registration: https://thaiclinicaltrials.org/ with identifier number TCTR20210823004.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11615492 | PMC |
http://dx.doi.org/10.1016/j.heliyon.2024.e40453 | DOI Listing |
Lecanemab, a humanized IgG1 monoclonal antibody that binds with high affinity to amyloid-beta (Aβ) protofibrils, was formally evaluated as a treatment for early Alzheimer's disease in a phase 2 study (Study 201) and the phase 3 Clarity AD study. These trials both included an 18-month, randomized study (core) and an open-label extension (OLE) phase where eligible participants received open-label lecanemab for up to 30 months to date. Clinical (CDR-SB, ADAS-Cog14, and ADCS-MCI-ADL), biomarker (PET, Aβ42/40 ratio, and ptau181) and safety outcomes were evaluated.
View Article and Find Full Text PDFAlzheimer's disease pathophysiology is believed to involve various abnormalities, including those of amyloid beta (Ab) peptide and tau processing, inflammation, oxidative stress, and vascular risk factors. Aβ peptides exist in a dynamic continuum of conformational states from monomeric Aβ, to soluble progressively larger Aβ assemblies that include a range of low molecular weight oligomers to higher molecular weight protofibrils, and finally to insoluble fibrils (plaques). Various lines of evidence support the "amyloid hypothesis" that Aβ plays a central role in the pathogenesis of AD, and several immunotherapies have been developed to interact with this cascade in various different places which may reduce the number of soluble aggregates and insoluble Aβ fibrils deposited in the brain.
View Article and Find Full Text PDFBackground: Lecanemab is an approved anti-amyloid monoclonal antibody that binds with highest affinity to soluble Aβ protofibrils, which are more toxic than monomers or insoluble fibrils/plaque. In clinical studies, biweekly lecanemab treatment demonstrated a slowing of decline in clinical (global, cognitive, functional, and quality of life) outcomes, and reduction in brain amyloid in early Alzheimer's disease (AD). Herein, we describe the impact of lecanemab treatment on tau PET.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Stevenson University, Owings Mills, MD, USA.
Background: Most assisted living (AL) settings organize and provide opportunities for residents to participate in activities (e.g., exercise, music, arts and craft, cognitive activities, religious services, community outings).
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!